MX2023008333A - Nanomateriales. - Google Patents

Nanomateriales.

Info

Publication number
MX2023008333A
MX2023008333A MX2023008333A MX2023008333A MX2023008333A MX 2023008333 A MX2023008333 A MX 2023008333A MX 2023008333 A MX2023008333 A MX 2023008333A MX 2023008333 A MX2023008333 A MX 2023008333A MX 2023008333 A MX2023008333 A MX 2023008333A
Authority
MX
Mexico
Prior art keywords
nanomaterials
nanoparticles
preparations
methods
present disclosure
Prior art date
Application number
MX2023008333A
Other languages
English (en)
Spanish (es)
Inventor
Cory Dane Sago
Gregory Lawrence Hamilton
Original Assignee
Beam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beam Therapeutics Inc filed Critical Beam Therapeutics Inc
Publication of MX2023008333A publication Critical patent/MX2023008333A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/16Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Lubricants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2023008333A 2021-01-20 2022-01-19 Nanomateriales. MX2023008333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163139734P 2021-01-20 2021-01-20
PCT/US2022/012941 WO2022159463A1 (en) 2021-01-20 2022-01-19 Nanomaterials

Publications (1)

Publication Number Publication Date
MX2023008333A true MX2023008333A (es) 2023-08-21

Family

ID=82549752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008333A MX2023008333A (es) 2021-01-20 2022-01-19 Nanomateriales.

Country Status (10)

Country Link
US (2) US12059477B2 (enExample)
EP (1) EP4281050A4 (enExample)
JP (1) JP2024502954A (enExample)
KR (1) KR20230131863A (enExample)
CN (1) CN116761888A (enExample)
AU (1) AU2022210313A1 (enExample)
CA (1) CA3203742A1 (enExample)
IL (1) IL303846A (enExample)
MX (1) MX2023008333A (enExample)
WO (1) WO2022159463A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3145913A1 (en) 2019-07-29 2021-02-04 James Everett Dahlman Nanomaterials containing constrained lipids and uses thereof
IL294318A (en) 2020-01-09 2022-08-01 Guide Therapeutics Llc Nanomaterials
EP4281080A4 (en) 2021-01-20 2025-09-24 Beam Therapeutics Inc NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
CN116761888A (zh) 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料
JP2024503441A (ja) * 2021-01-20 2024-01-25 ビーム セラピューティクス インク. イオン化可能な脂質を含むナノ材料
CA3260437A1 (en) 2022-07-20 2024-01-25 Beam Therapeutics Inc. NANOMATERIALS INCLUDING TRIOLS
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110977A (en) 1990-02-14 1992-05-05 Eastman Kodak Company Ester-containing quaternary ammonium salts as adhesion improving toner charge agents
US20030083272A1 (en) 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
CN107879960B (zh) 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10125092B2 (en) 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2880103T3 (es) * 2015-05-21 2021-11-23 Ohio State Innovation Foundation Derivados de benceno-1, 3, 5-tricarboxamida y usos de los mismos
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
CN120682290A (zh) 2017-07-04 2025-09-23 尹图赛利有限公司 包含可裂解接头的化合物及其用途
CA3081414A1 (en) 2017-10-30 2019-05-09 Georgia Tech Research Corporation Multiplexed analysis of materials for tissue delivery
US11622942B2 (en) 2017-11-14 2023-04-11 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof
US20220009878A1 (en) 2018-10-02 2022-01-13 Intellia Therapeutics, Inc. Ionizable amine lipids
BR112021010853A2 (pt) * 2018-12-05 2021-08-31 Intellia Therapeutics, Inc. Lipídios de amina modificados
CN119700703A (zh) 2019-01-17 2025-03-28 佐治亚技术研究公司 含有氧化的胆固醇的药物递送系统
JP7693552B2 (ja) 2019-02-13 2025-06-17 ビーム セラピューティクス インク. アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法
CN114127044A (zh) 2019-04-25 2022-03-01 英特利亚治疗股份有限公司 可电离的胺类脂质和脂质纳米颗粒
JP2022536112A (ja) 2019-06-05 2022-08-12 ガイド セラピューティクス,インコーポレーテッド 組織送達のための材料の分析
CA3145913A1 (en) 2019-07-29 2021-02-04 James Everett Dahlman Nanomaterials containing constrained lipids and uses thereof
WO2021021636A1 (en) 2019-07-29 2021-02-04 Georgia Tech Research Corporation Oligonucleotide antagonists for rna guided genome editing
KR20220113737A (ko) 2019-12-06 2022-08-16 가이드 테라퓨틱스 엘엘씨 나노물질
IL294318A (en) 2020-01-09 2022-08-01 Guide Therapeutics Llc Nanomaterials
EP4262819A4 (en) 2020-12-21 2024-12-04 Beam Therapeutics Inc. NANOMATERIALS WITH ESTER-BOUND ACETALS
EP4262818A4 (en) 2020-12-21 2025-03-26 Beam Therapeutics Inc. NANOMATERIALS WITH CARBONATES
JP2024503976A (ja) 2020-12-21 2024-01-30 ビーム セラピューティクス インク. アセタールを含むナノ材料
EP4281080A4 (en) 2021-01-20 2025-09-24 Beam Therapeutics Inc NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
CN116761888A (zh) 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料
JP2024503441A (ja) 2021-01-20 2024-01-25 ビーム セラピューティクス インク. イオン化可能な脂質を含むナノ材料
CA3203784A1 (en) 2021-01-20 2022-07-28 Beam Therapeutics Inc. Ionizable lipids for nanomaterials
EP4452925A1 (en) 2021-12-20 2024-10-30 Beam Therapeutics Inc. Nanomaterial comprising diamines
WO2023121970A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Ionizable amine and ester lipids and lipid nanoparticles
CA3241488A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Ionizable amine lipids and lipid nanoparticles
JP2025500824A (ja) 2021-12-20 2025-01-15 ビーム セラピューティクス インク. 四価脂質化合物を含むナノ材料
EP4452942A1 (en) 2021-12-20 2024-10-30 Beam Therapeutics Inc. Nanomaterials comprising disulfides

Also Published As

Publication number Publication date
EP4281050A4 (en) 2025-05-21
KR20230131863A (ko) 2023-09-14
AU2022210313A1 (en) 2023-06-29
JP2024502954A (ja) 2024-01-24
AU2022210313A9 (en) 2024-05-02
US20220249693A1 (en) 2022-08-11
EP4281050A1 (en) 2023-11-29
US20250041441A1 (en) 2025-02-06
CN116761888A (zh) 2023-09-15
US12059477B2 (en) 2024-08-13
CA3203742A1 (en) 2022-07-28
IL303846A (en) 2023-08-01
WO2022159463A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
MX2023008333A (es) Nanomateriales.
MX2025000643A (es) Nanomateriales que comprenden trioles
MX2023007137A (es) Nanomateriales que comprenden acetales unidos a ésteres.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2023005697A (es) Composiciones y metodos para la estabilizacion de vacunas de arnm en nanoparticulas lipidicas.
MX2024013597A (es) Composiciones de nanoparticulas lipidicas para suministro de agentes biologicamente activos
MX2025003080A (es) Conjugados de il-15, y sus usos
PH12022551522A1 (en) Smarca degraders and uses thereof
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
WO2020172420A3 (en) Stable anhydrous cleanser concentrate formulation and method of making same
MX2023008328A (es) Nanomateriales que comprenden una caracteristica biodegradable.
EP4279071A3 (en) Novel cannabinoid formulations
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
ZA202309516B (en) Anti-ccr8 antibodies
ZA201905023B (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
EP4233843A3 (en) Antibody compositions
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
MX2020013732A (es) Metodos de fabricacion de composiciones de aminoacidos.
GB2568181A (en) Wheat
MX2021009108A (es) Nanoproductos microbicidas y microbiostaticos de amplio espectro y formulaciones, preparaciones y metodos para su uso.
WO2018189661A3 (en) Methods and compounds for treating diabetes
WO2020146700A8 (en) Lipid nanoparticles
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
CA3010771A1 (en) Combination therapy with an iron compound and a citrate compound